Chemicals of Shanghai APIs Chemical Co.,
|CAS Registry Number:
Information about this agent
GPX-150 is a synthetic non-cardiotoxic analogue
of the anthracycline antibiotic doxorubicin with
potential antineoplastic activity. Anthracycline
analogue GPX-150 intercalates DNA and impedes
the activity of topoisomerase II, inducing
single and double-stranded breaks in DNA;
inhibiting DNA replication and/or repair,
transcription, and protein synthesis; and
activating tumor cell apoptosis. Check for
active clinical trials or closed clinical trials
using this agent. (NCI Thesaurus).
As of August 2010, GPX-150 is under Phase I
clinical trials sponsored by Coronado
Biosciences, Inc. This is a Phase 1 safety and
dose escalation study to define the maximum
tolerated dose (MTD) and identify the dose
limiting toxicities (DLT) following IV
administration of GPX-150 once every 3 weeks.
Escalating doses starting at the dose of 14
mg/m2 and increasing to the dose of 265 mg/m2
will be administered IV once every 3 weeks for
up to 8 cycles of treatment. Patients who have
previously received an anthracycline are limited
to 4 cycles of treatment. (source: http://clinicaltrials.gov/ct2/show/NCT00710125).
Current developer: Gem Pharmaceuticals, Inc and
ACCESS Oncology, Inc.